SLC5A2 and chronic kidney disease: Heerspink et al. investigated the effect of dapagliflozin (10 mg once a day) in CKD patients with or without type 2 diabetes and demonstrated that dapagliflozin significantly improved the clinical outcomes of CKD patients by inhibiting SGLT2 regardless of the absence or presence of diabetes [139].